Skip to main content

Qinlock Side Effects

Generic name: ripretinib

Medically reviewed by Last updated on Mar 31, 2024.

Note: This document contains side effect information about ripretinib. Some dosage forms listed on this page may not apply to the brand name Qinlock.

Applies to ripretinib: oral tablet.

Serious side effects of Qinlock

Along with its needed effects, ripretinib (the active ingredient contained in Qinlock) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ripretinib:

More common

Less common


Other side effects of Qinlock

Some side effects of ripretinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to ripretinib: oral tablet.


The most common adverse reactions are alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (PPES), and vomiting.[Ref]


Very common (10% or more): Hypertension (up to 19.4%)

Common (1% to 10%): Cardiac dysfunction (e.g., cardiac failure, acute left ventricular failure, diastolic dysfunction, ventricular hypertrophy), cardiac ischemic events (including acute coronary syndrome and fatal cardiac arrest or myocardial infarction)[Ref]


Very common (10% or more): Alopecia (up to 52%), palmar-plantar erythrodysesthesia syndrome (PPES) (up to 29.8%), dry skin (up to 17%), pruritus (11%)

Common (1% to 10%): Photosensitivity

Frequency not reported: Dermatosis[Ref]


Very common (10% or more): Nausea (39%), abdominal pain (36%), constipation (34%), lipase increased (32%), diarrhea (28%), vomiting (21%), serum amylase increased (13%), stomatitis (11%)[Ref]


Common (1% to 10%): Anemia (3.5%)[Ref]


Very common (10% or more): Increased bilirubin (22%), increased alanine aminotransferase (ALT) (12%)[Ref]


Very common (10% or more): Decreased appetite (27%)[Ref]


Very common (10% or more): Myalgia (up to 37.8%), arthralgia (up to 21.2%), muscle spasms (15%)

Frequency not reported: Arthritis[Ref]

Nervous system

Very common (10% or more): Headache (up to 20.7%)

Frequency not reported: Hyperesthesia[Ref]


Common (1% to 10%): Cutaneous squamous cell carcinoma, keratoacanthoma, melanoma[Ref]


Very common (10% or more): Fatigue (up to 51%), increased creatine phosphokinase (CPK) (21%), peripheral edema (up to 17%), asthenia (13%), increased triglycerides (26%), decreased phosphate (26%), decreased calcium (23%), weight loss (up to 26.5%), decreased sodium (17%), increased activated partial thromboplastin time (35%), increased international normalized ration (INR) (21%), decreased neutrophil count (10%), increased lipase (up to 32%), increased serum amylase (13%)

Common (1% to 10%): Physical health deterioration[Ref]


Frequency not reported: Agitation[Ref]


Very common (10% or more): Increased creatinine (16%)[Ref]


Very common (10% or more): Dyspnea (up 20.2%)[Ref]


1. Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals (Netherlands) B.V. 2023.

2. Product Information. Qinlock (ripretinib). Specialised Therapeutics Australia Pty Ltd. 2022.

3. Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.